Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

Abstract Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options for adolescents with moderate-to-severe disease. Lebrikizumab, a monoclonal antibody targeting interleukin (IL)-13, demonstrated clinical benefit in previous Phase 3 trials: ADvocate1...

Full description

Bibliographic Details
Main Authors: Amy S. Paller, Carsten Flohr, Lawrence F. Eichenfield, Alan D. Irvine, Jamie Weisman, Jennifer Soung, Ana Pinto Correia, Chitra R. Natalie, Claudia Rodriguez Capriles, Evangeline Pierce, Sarah Reifeis, Renata Gontijo Lima, Clara Armengol Tubau, Vivian Laquer, Stephan Weidinger
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-06-01
Series:Dermatology and Therapy
Subjects:
Adolescents
Efficacy
IL-13
Lebrikizumab
Moderate-to-severe atopic dermatitis
Safety
Online Access:https://doi.org/10.1007/s13555-023-00942-y

Internet

https://doi.org/10.1007/s13555-023-00942-y

Similar Items